Artificial oxygen carriers - A critical analysis

Infusionstherapie und Transfusionsmedizin

Volumn 29, Issue 3, 2002, Pages 167-174

  Dinkelmann, S ^a   Northoff, Hinnak ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Blood substitutes; Hemoglobin solutions; Nitric oxide scavenger; Oxygen carrier; Perfluorocarbons

Indexed keywords

DEXAMETHASONE; DIASPIRIN CROSSLINKED HEMOGLOBIN; ENDOTOXIN; FLUOROCARBON; FLUOSOL DA; HEMOGLOBIN; HEMOGLOBIN DERIVATIVE; NITRIC OXIDE DONOR; PERFLUORODECALIN; PERFLUOROOCTYL BROMIDE; PHOSPHATIDYLCHOLINE; POLOXAMER; POLYMERIZED HEMOGLOBIN; RECOMBINANT HEMOGLOBIN; UNCLASSIFIED DRUG; VTR PHP;

ABDOMINAL PAIN; ANTIGENICITY; BLOOD VESSEL REACTIVITY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG APPROVAL; DRUG BINDING; DRUG HYPERSENSITIVITY; DRUG MARKETING; FEVER; GASTROINTESTINAL SYMPTOM; HEMORRHAGIC SHOCK; HUMAN; IMMUNE DEFICIENCY; JAUNDICE; LEUKOPENIA; MOLECULAR SIZE; NAUSEA; NEPHROTOXICITY; OXYGEN TRANSPORT; STROKE; THROMBOCYTOPENIA; VISCOSITY;

BOVINAE;

EID: 0036067078     PISSN: 14245485     EISSN: None     Source Type: Journal    
DOI: 10.1159/000064237     Document Type: Conference Paper

References (68)

1. Blood product from cattle wins approval for use in humans
2. Fluorocarbon-based-oxygen-delivery: Basic principles and product development
3. Perfluorocarbons in the twenty-first century: Clinical applications as transfusion alternatives
4. Perfluorochemical emulsions: Future alternatives to transfusion
5. Perfluorochemical emulsions as blood substitutes: Clinical data and new applications
6. Phagocytosis of colloidal carbon after administration of perfluorochemicals of first and second generation
7. Perfluorochemical emulsions decrease Kupffer cell phagocytosis
8. Red blood cell substitutes
9. A system establishment compatibility profiles for artificial oxygen carriers and other substances
10. Pharmacologic pertubation of neutrophils by Fluosol results in a sustained reduction in infarct size in the canine model of reperfusion
11. Clinical studies of a perfluorochemical whole blood substitute (Fluosol-DA) Summary of 186 cases
12. Perfluorocarbons as blood substitutes: The early years. Experience with Fluosol DA-20% in the 1980s
13. Intravenous Fluosol in the treatment of acute myocardial infarction. Results of the Thrombolysis and Angioplasty in Myocardial Infarction 9 Trial
14. Development and clinical application of perfluorochemical artificial blood
15. Complement activation by artificial blood substitute Fluosol: In vitro and in vivo studies
16. Clinical development of perfluorocarbon-based emulsions as red cell substitutes
17. Perflubron emulsion delays blood transfusions in orthopedic surgery
18. Liquid ventilation: Clinical experiences
19. Partial liquid ventilation in adult patients with ARDS: A multicenter phase I-II trial
20. Clinical experience with AF0150 (Imagent US), a new ultrasound contrast agent
21. A human recombinant haemoglobin designed for use as a blood substitute
22. Recombinant hemoglobin A produced in transgenic swine: Structural equivalence with human hemoglobin A
23. New artificial oxygen carriers made of pegulated pyridoxylated porcine haemoglobin (P4Hb)
24. Effect of diaspirin cross-linked hemoglobin on endothelin-1 and blood pressure in acute ischemic stroke in man
25. Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock: A randomized controlled efficacy trial
26. Controlled safety study of a hemoglobin-based oxygen carrier, DCLHb, in acute ischemic stroke
27. Oxygen therapeutics - Current concepts
28. Safety and efficacy of o-raffinose cross-linked human hemoglobin (Hemolink) in cardiac surgery
29. Hemolink, an o-raffinose crosslinked hemoglobin-based oxygen carrier
30. The clinical development of human polymerized hemoglobin
31. The first randomized trial of human polymerized hemoglobin as a blood substitute in acute trauma and emergent surgery
32. Pyridoxalated hemoglobin polyoxyethylene: A nitric oxide scavenger with antioxidant activity for the treatment of nitric oxide-induced shock
33. Serum antibody titers in rats receiving repeated small subcutaneous injections of hemoglobin or polyhemoglobin: A preliminary report
34. Immunological effects of hemoglobin, encapsulated hemoglobin, polyhemoglobin and conjugated hemoglobin using different immunization schedules
35. Evaluation of the immunogenicity of polymerized hemoglobin solutions in a rabbit model
36. Absence of immunopathology associated with repeated IV administration of bovine Hb-based oxygen carrier in dogs
37. Absence of immunogenicity of diaspirin cross-linked hemoglobin in humans
38. Limitations of the efficacy of hemoglobin-based oxygen-carrying solutions
39. Methemoglobin formation after administration of hemoglobin conjugated to carboxylate dextran in guinea pigs. Attempts to prevent the oxidation of hemoglobin
40. Diaspirin crosslinked hemoglobin (DCLHb): Bioanalytical studies in swine
41. Enzymatic protection from autoxidation for crosslinked hemoglobins
42. Reaction of human endothelial cells to bovine hemoglobin solutions and tumor necrosis factor
43. Cell-free hemoglobin and tissue oxidants: Probing the mechanisms of hemoglobin cytotoxicity
44. Hemoglobin increases mortality from bacterial endotoxin
45. Synergistic toxicity of endotoxin and hemoglobin
46. Interactions of recombinant hemoglobin (rHb1.1) and endotoxin in vivo: Effects on systemic tumor necrosis factor and interleukin-6 levels in lethal and sublethal murine models of endotoxemia
47. Effect of liposome-encapsulated hemoglobin on the development of endotoxin-induced shock in the rat
48. Oxalated pyridoxalated hemoglobin polyoxyethylene conjugate normalizes the hyperdynamic circulation in septic sheep
49. Polymerized hemoglobin restores cardiovascular and kidney function in endotoxin-induced shock in the rat
50. alphaalpha-crosslinked hemoglobin: Was failure predicted by preclinical testing?
51. The effects of increased doses of bovine hemoglobin on hemodynamics and oxygen transport in patients undergoing preoperative hemodilution for elective abdominal aortic surgery
52. Rate of reaction with nitric oxide determines the hypertensive effect of cell-free hemoglobin
53. Nonpeptide endothelin receptor antagonists attenuate the pressor effect of diaspirin-crosslinked hemoglobin in rat
54. Endothelin plays a role in contractions of isolated pig pulmonary vessels induced by diaspirin cross-linked hemoglobin
55. Clinical development of human polymerized hemoglobin as a blood substitute
56. Modified hemoglobins produce venular interendothelial gaps and albumin leakage in the rat mesentery
57. Arterial blood pressure responses to cell-free hemoglobin solutions and the reaction with nitric oxide
58. A theoretical analysis of oxygen transport: A new strategy for the design of hemoglobin-based red cell substitutes
59. Microcirculatory consequences of blood substitution with aa-hemoglobin
60. Oxygen transport by erythrocyte/hemoglobin solution mixtures in an in vitro capillary as a model of hemoglobin-based oxygen carrier performance
61. The role of facilitated diffusion in oxygen transport by cell-free hemoglobins: Implications for the design of hemoglobin-based oxygen carriers
62. Novel recombinant hemoglobin, rHb (beta N108Q), with low oxygen affinity, high cooperativity, and stability against autoxidation
63. Preparation and characterization of SNO-PEG-hemoglobin as a candidate for oxygen transporting material
64. Haemoglobin-based oxygen carriers
65. Inhibition of endothelium-dependent relaxation by hemoglobin in rabbit aortic strips: Comparison between acellular hemoglobin derivatives and cellular hemoglobins
66. Submicron polymer membrane hemoglobin nanocapsules as potential blood substitutes: Preparation and characterization
67. Polyethylene glycol-modified liposome-encapsulated hemoglobin: A long circulating red cell substitute